Acrivon Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Acrivon Therapeutics Inc 's ROA in the second quarter of 2026?
Acrivon Therapeutics Inc recorded a cumulative net loss of $-74 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -61.72%.

However, within the Healthcare sector 623 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4001, from total ROA ranking in the first quarter of 2026 at 4603.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-35.87 %	-38.1 %	-33.2 %	-32.57 %	-31.93 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-74	-77	-78	-82	-86
Return On Assets (TTM)	-61.72 %	-57.57 %	-51.66 %	-48.97 %	-46.65 %
ACRV's Total Ranking	# 4001	# 4603	# 4004	# 4033	# 4031
Total Assets (TTM) in million	100	108	130	144	156
Seq. Total Assets Change	-7.41 %	-16.87 %	-9.7 %	-7.72 %	-10.63 %
Seq. Net Income Change	-	-	-	-	-

ACRV's 5 Years Annual ROA >> Back to ACRV Management Effectiveness >> Compare ACRV ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 279
Sector	# 624
Overall	# 4010

Return On Assets Statistics
High	Average	Low
-26.9 %	-43.23 %	-61.61 %
(Mar 31 2023)		(Jun 30 2026)

News about Acrivon Therapeutics Inc Return on Assets ROA

Innovative Cancer Therapy Acrivon Therapeutics Embarks on Phase 1 Trial with Advanced WEE1/PKMYT1 Inhibito...

In the dynamic field of cancer therapeutics, pioneering research and early-stage clinical trials are crucial steps in the development of novel treatment options. Acrivon Therapeutics, a biotechnology company committed to precision oncology, has recently announced a significant milestone in its research endeavors. The company has initiated the first patient dosing in its Phase 1 clinical trial of ACR-2316, a cutting-edge WEE1/PKMYT1 inhibitor.The commencement of this trial marks a noteworthy achievement, as the milestone has been reached two quarters ahead of the original schedule. This accelerated timeline underscores Acrivon s robust commitment to advancing therapy options for patients who are grappling with the challenges of cancer. ACR-2316 is a sophisticated therapeutic candidate crafted using Acrivon s proprietary AP3 platform aimed at identifying optimal therapeutic profiles. This platform has been instrumental in designing ACR-2316 as a superior single-agent treatment, targeting critical cell cycle regulators, WEE1 and PKMYT1. These targets are essential in the survival and proliferation of cancer cells, making them vital opponents in the battle against a myriad of cancer types.

Financial Statements
Acrivon Therapeutics Inc 's Assets	$ 100 million	ACRV's Balance sheet
Acrivon Therapeutics Inc 's Income	$ -18 million	Quarterly ACRV's Income Statement
ACRV's Income by Division		See ACRV's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	FY
Y / Y Total Assets Change	-33.2 %	43.66 %	-24.09 %	-	-
Total Assets in million	130	194	135	178	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-78	-81	-60	-31	0
Annual Return On Assets	-60.06 %	-41.48 %	-44.68 %	-17.5 %	-

ACRV's 5 Years Annual ROA >> Back to ACRV Management Effectiveness >> Compare ACRV ROA to its Competitors

More Return On Assets Ratios
ACRV's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ACRV's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ACRV's Competitors
Subscribers only: Roa for Acrivon Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for ACRV's Customers

You may also want to know
ACRV's Roi	ACRV's Inventory Turnover Ratio	ACRV's Growth Rates	ACRV's Dividend Comparisons
	ACRV's Profitability Ratios	ACRV's Asset Turnover Ratio	ACRV's Dividend Growth
ACRV's Roe	ACRV's Valuation Ratios	ACRV's Financial Strength Ratios	ACRV's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:39:09+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.